Tens of millions of J&J COVID-19 shots sit at Baltimore factory -sources

EXCLUSIVE Tens of millions of J&J COVID-19 shots sit at Baltimore factory -sources An estimated 30 million to 50 million doses of Johnson & Johnson's COVID-19 vaccine made early this year sits idle in Emergent BioSolutions Inc's plant in Baltimore awaiting a green light from U.S. regulators to ship, two sources familiar with the matter said. Carl O'donnell Reuters

Oct 28 (Reuters) - An estimated 30 million to 50 million doses of Johnson & Johnson's (JNJ.N) COVID-19 vaccine made early this year sits idle in Emergent BioSolutions Inc's (EBS.N) plant in Baltimore awaiting a green light from U.S. regulators to ship, two sources familiar with the matter said.

Emergent, a contract drug manufacturer, is waiting for the U.S. Food and Drug Administration to approve release of those doses. The agency must still inspect and authorize the plant before Emergent can ship newly manufactured drug substance, one of the sources said...

The FDA in April halted operations at Emergent's production facility after J&J's vaccine was found to be contaminated with material from AstraZeneca's (AZN.L) COVID-19 shots, which were also being manufactured there at the time. ...